Show simple item record

atmire.cua.enabled
dc.contributor.authorYin, T.
dc.contributor.authorHe, S.
dc.contributor.authorSu, Chao
dc.contributor.authorChen, X.
dc.contributor.authorZhang, D.
dc.contributor.authorWan, Y.
dc.contributor.authorYe, T.
dc.contributor.authorShen, G.
dc.contributor.authorWang, Y.
dc.contributor.authorShi, H.
dc.contributor.authorYang, L.
dc.contributor.authorWei, Y.
dc.date.accessioned2017-08-24T02:21:37Z
dc.date.available2017-08-24T02:21:37Z
dc.date.created2017-08-23T07:21:44Z
dc.date.issued2015
dc.identifier.citationYin, T. and He, S. and Su, C. and Chen, X. and Zhang, D. and Wan, Y. and Ye, T. et al. 2015. Genetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia. Molecular Medicine Reports. 12 (4): pp. 5093-5099.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/55943
dc.identifier.doi10.3892/mmr.2015.4089
dc.description.abstract

Ischemic diseases represent a challenging worldwide health burden. The current study investigated the therapeutic potential of genetically modified human placenta-derived mesenchymal stem cells (hPDMSCs) with basic fibroblast growth factor (FGF2) and platelet-derived growth factor-BB (PDGF-BB) genes in hindlimb ischemia. Mesenchymal stem cells obtained from human term placenta were transfected ex vivo with adenoviral bicistronic vectors carrying the FGF2 and PDGF-BB genes (Ad-F-P). Unilateral hindlimb ischemia was surgically induced by excision of the right femoral artery in New Zealand White rabbits. Ad-F-P genetically modified hPDMSCs, Ad-null (control vector)-modified hPDMSCs, unmodified hPDMSCs or media were intramuscularly implanted into the ischemic limbs 7 days subsequent to the induction of ischemia. Four weeks after cell therapy, angiographic analysis revealed significantly increased collateral vessel formation in the Ad-F-P-hPDMSC group compared with the control group. Histological examination revealed markedly increased capillary and arteriole density in the Ad-F-P-hPDMSC group. The xenografted hPDMSCs survived in the ischemic tissue for at least 4 weeks subsequent to cell therapy. The current study demonstrated that the combination of hPDMSC therapy with FGF2 and PDGF-BB gene therapy effectively induced collateral vessel formation and angiogenesis, suggesting a novel strategy for therapeutic angiogenesis.

dc.publisherSpandidos Publications
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titleGenetically modified human placenta-derived mesenchymal stem cells with FGF-2 and PDGF-BB enhance neovascularization in a model of hindlimb ischemia
dc.typeJournal Article
dcterms.source.volume12
dcterms.source.number4
dcterms.source.startPage5093
dcterms.source.endPage5099
dcterms.source.issn1791-2997
dcterms.source.titleMolecular Medicine Reports
curtin.departmentDepartment of Chemical Engineering
curtin.accessStatusOpen access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/